The underlying mechanisms of the inhibitory effect of YD0514 on breast cancer cells occurs through reduced expression of MMP-9, MMP-2, and FAK as well as integrin family members in addition to integrin β1, so researchers speculated that YD0514 retained the antimetastatic property of oridonin and exerted its anticancer effect via inhibition of the integrin/FAK pathway [90]. The gene discussed is PTK2; the disease is breast cancer.